glp-1 cardiovascular outcomes 2025 news Agonists in Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies The cardiovascular effects of GLP-1

Healthy Weight and Growth

Clinical trial data from the STEP 1 extension study showed that after discontinuing semaglutide 2.4 mg, approximately two-thirds of weight loss was regained within one year

Frequently Asked Questions What is a lower body lift after gastric bypass

Based on VigiBase, the World Health Organizations (WHO) adverse drug reaction database, intestinal obstructions are reported over 4.5 times more frequently with incretin-based drugs than with other diabetes medications [10]

In addition, recurrent hypoglycemia exacerbates the defective responses to subsequent hypoglycemia, thus leading to a vicious circle of reduced awareness, increased vulnerability and further episodes of hypoglycemia (Figure 13.7)

This is because the medication is still undergoing further trials to ensure its safety and suitability for long-term use